RT Journal Article
T1 Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension.
A1 Guillen-Del-Castillo, Alfredo
A1 Meseguer, Manuel López
A1 Fonollosa-Pla, Vicent
A1 Gimenez, Berta Sáez
A1 Colunga-Argüelles, Dolores
A1 Revilla-Lopez, Eva
A1 Rubio-Rivas, Manuel
A1 Ropero, Maria Jose Cristo
A1 Argibay, Ana
A1 Barbera, Joan Albert
A1 Salas, Xavier Pla
A1 Meñaca, Amaya Martínez
A1 Vuelta, Ana Belen Madroñero
A1 Padron, Antonio Lara
A1 Comet, Luis Saez
A1 Morera, Juan Antonio Domingo
A1 Gonzalez-Echavarri, Cristina
A1 Mombiela, Teresa
A1 Ortego-Centeno, Norberto
A1 Gonzalez, Manuela Marín
A1 Tolosa-Vilella, Carles
A1 Blanco, Isabel
A1 Subias, Pilar Escribano
A1 Simeon-Aznar, Carmen Pilar
AB To assess severity markers and outcomes of patients with systemic sclerosis (SSc) with or without pulmonary arterial hypertension (PAH-SSc/non-PAH-SSc), and the impact of interstitial lung disease (ILD) on PAH-SSc. Non-PAH-SSc patients from the Spanish SSc registry and PAH-SSc patients from the Spanish PAH registry were included. A total of 364 PAH-SSc and 1589 non-PAH-SSc patients were included. PAH-SSc patients had worse NYHA-functional class (NYHA-FC), worse forced vital capacity (FVC) (81.2 ± 20.6% vs 93.6 ± 20.6%, P 
PB Nature Publishing Group
YR 2022
FD 2022-03-11
LK http://hdl.handle.net/10668/19596
UL http://hdl.handle.net/10668/19596
LA en
NO Guillén-Del-Castillo A, Meseguer ML, Fonollosa-Pla V, Giménez BS, Colunga-Argüelles D, et al. Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary arterial hypertension. Sci Rep. 2022 Mar 28;12(1):5289. doi: 10.1038/s41598-022-09353-z. Erratum in: Sci Rep. 2022 Jul 28;12(1):12947.
DS RISalud
RD Apr 19, 2025